| pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Phase 2 | Active not recruiting | 340 | Feb 12, 2027 |
| Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | Phase 3 | Active not recruiting | 520 | Jan 31, 2027 |
| 9vHPV Vaccine | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | Phase 3 | Active not recruiting | 6,033 | Jan 15, 2027 |
| Sacituzumab Govitecan | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | Phase 3 | Active not recruiting | 614 | Jan 12, 2027 |
| sac-TMT | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Phase 3 | Active not recruiting | 450 | Jan 4, 2027 |
| SOC: Temozolomide | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | Phase 2 | Active not recruiting | 99 | Jan 2027 |
| Keytruda Injectable Product | Metastatic Solid Cancer Clinical Trial | Phase 2 | Completed | 32 | Nov 10, 2026 |
| Pembrolizumab injection | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) | Phase 2 | Terminated | 22 | Oct 1, 2026 |
| sac-TMT | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Phase 2 | Completed | 35 | Sep 30, 2026 |
| PREVYMIS | De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients | Phase 3 | Completed | 30 | Sep 1, 2026 |
| ONC-392 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Phase 2 | Active not recruiting | 58 | Aug 30, 2026 |
| Avelumab | Avelumab Program Rollover Study | Phase 3 | Active not recruiting | 205 | Aug 21, 2026 |
| GSK2636771 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | Phase 2 | Completed | 28 | Aug 20, 2026 |
| Raludotatug Deruxtecan (R-DXd) | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Phase 2 | Active not recruiting | 160 | Aug 18, 2026 |
| Ensifentrine 3 mg | Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | Phase 2 | Completed | 497 | Aug 17, 2026 |
| Tuvusertib (M1774) | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Phase 2 | Completed | 63 | Aug 11, 2026 |
| Pembrolizumab | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Phase 2 | Completed | 393 | Aug 10, 2026 |
| Suvorexant | Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl | Phase 2 | Completed | 76 | Aug 3, 2026 |
| — | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Phase 2 | Completed | 85 | Aug 3, 2026 |
| IV Tulisokibart | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Phase 3 | Active not recruiting | 1,020 | Aug 1, 2026 |
| Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Phase 3 | Active not recruiting | 1,397 | Jul 31, 2026 |
| Pembrolizumab | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | Phase 2 | Completed | 263 | Jul 23, 2026 |
| Belzutifan | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | Phase 2 | Active not recruiting | 60 | Jul 21, 2026 |
| M1774 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Phase 2 | Completed | 61 | Jul 15, 2026 |
| Pembrolizumab | Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma | Phase 2 | Completed | 31 | Jul 15, 2026 |
| Pembrolizumab | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer | Phase 2 | Completed | 31 | Jul 7, 2026 |
| Pembrolizumab | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Phase 3 | Active not recruiting | 870 | Jul 6, 2026 |
| Ivermectin | Efficacy of Ivermectin in the Treatment of Plane Warts | Phase 2 | Completed | 80 | Jul 1, 2026 |
| ANV600 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Phase 2 | Completed | 63 | Jun 22, 2026 |
| Pembrolizumab, paclitaxel | Pembrolizumab and Paclitaxel in Hypermutated Breast Cancer | Phase 2 | Completed | 52 | Jun 19, 2026 |
| pembrolizumab/vibostolimab | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | Phase 3 | Completed | 610 | Jun 15, 2026 |
| Olaparib | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | Phase 2 | Completed | 333 | Jun 8, 2026 |
| MK-1167 | A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Phase 2 | Terminated | 369 | Jun 5, 2026 |
| 200 mg Pembrolizumab | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Phase 2 | Active not recruiting | 23 | Jun 2026 |
| Pembrolizumab | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | Phase 2 | Completed | 335 | May 18, 2026 |
| Cetuximab | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC | Phase 2 | Completed | 16 | May 12, 2026 |
| ASP1570 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Phase 2 | Terminated | 226 | May 11, 2026 |
| Nab-paclitaxel | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Phase 2 | Completed · results | 36 | May 7, 2026 |
| Pembrolizumab | RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy | Phase 2 | Completed | 6 | May 1, 2026 |
| Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Phase 2 | Completed | 26 | Apr 24, 2026 |